The use of inhaled prostacyclin in nitroprusside-resistant pulmonary artery hypertension

Journal of Heart and Lung Transplantation

Volumn 20, Issue 12, 2001, Pages 1340-1344

  Weston, Mark W ^a,b   Isaac, Barton F ^b   Crain, Christine ^b  

^a LifeLink Transplant Institute   (United States)

^b TAMPA GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NITROPRUSSIDE SODIUM; PROSTACYCLIN;

ADULT; ARTERY DILATATION; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; FEMALE; HEART TRANSPLANTATION; HEMODYNAMIC MONITORING; HUMAN; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; VASCULAR RESISTANCE;

ADMINISTRATION, INHALATION; ADULT; DRUG RESISTANCE; EPOPROSTENOL; FEMALE; HEART TRANSPLANTATION; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITROPRUSSIDE; PREOPERATIVE CARE; PULMONARY WEDGE PRESSURE; VASCULAR RESISTANCE;

EID: 0035663956     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(01)00320-5     Document Type: Article

References (22)

1. Determinants of operative risk in human heart transplantation
2. Pulmonary vascular resistance and the risk of heart transplantation
3. Elevated pulmonary vascular resistance and cardiac transplantation
4. Vasodilator therapy after heart transplantation: Effects of inhaled nitric oxide and intravenous prostacyclin, prostaglandin E and sodium nitroprusside
5. Reversibility of pulmonary hypertension in congestive heart failure patients evaluated for cardiac transplantation: Comparative effects of various pharmacologic agents
6. Pulmonary vasodilation after heart transplantation: A comparison among prostacyclin, sodium nitroprusside and nitroclycerin on right ventricular function and pulmonary selectivity
7. Inhaled nitric oxide in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance
8. Evaluation of a new system for ventilatory administration of nitric oxide
9. Inhaled nitric oxide: A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction
10. Prostaglandins: Their disappearance from and release into the circulation
11. Biology and therapeutic potential of prostacyclin
12. Inhaled prostacyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: A pharmacodynamic study
13. 2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction
14. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome
15. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance
16. Effects of prostacyclin on the pulmonary vascular tone and cardiac contracticity of patients with pulmonary hypertension secondary to end-stage heart failure
17. A comparison of continuous intravenous prostacyclin versus conventional therapy in primary pulmonary hypertension
18. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
19. Reduction in pulmonary vascular resistance with long-term prostacyclin therapy in primary pulmonary hypertension
20. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
21. Pulmonary and antiaggregatory effects of prostacyclin after inhalation of intravenous infusion
22. 2) for 8 hours does not provide signs of acute pulmonary toxicity in healthy lambs